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Eric J NestlerThe following work is a translation and update of the fore-
word to the textbook “Molekulare Psychiatrie” [1]
reproduced with kind permission from the publisher and
its Editorial Director, Dr. K. Reinhardt.
One day, in 1987, Ron Duman and I were setting up our
new laboratories in CMHC, the Connecticut Mental
Health Center, a state mental hospital jointly run by the
State of Connecticut and Yale University. Since the 1960’s,
CMHC was unique as a state mental hospital in that it
included a basic neuroscience research group embedded
within inpatient and outpatient units that care for the
area’s mentally ill. Duman and I were newly hired assistant
professors and our appointments at Yale were made
possible by the conversion of a basement corridor, which
had heretofore been used to teach psychiatry residents
group and family therapy, into biochemical laboratories.
As Duman and I were setting up our new labs, we decided
to name our corridor “The Laboratory of Molecular
Psychiatry,” and we had the gumption to post a huge sign
with this new name, which we had made at a local photo-
copying store, without any permission from our higher-
ups. Thus was born the field of Molecular Psychiatry!
The name Molecular Psychiatry was particularly provoca-
tive in 1987. One of our fellow faculty researchers, a behav-
ioral neuroscientist, posted a sign on his laboratory,
“Laboratory of Molecular Fear.” Another faculty member in
the department labeled his office, “Laboratory of Molecular
Psychoanalysis.” I’m not sure what was most discomfiting
about Molecular Psychiatry. The name made eminent sense
to Duman and me, and our primary mentors at Yale,
George Heninger and George Aghajanian. The 1980’s
marked the dawn of the molecular revolution in medicine
and we all believed that brain diseases that manifest them-
selves in behavioral abnormalities would prove to be no dif-
ferent from diseases of all other organ systems, namely,
that psychiatric disorders have fundamental molecular le-
sions that need to be identified and understood and, with
that knowledge, reversed or prevented.Correspondence: eric.nestler@mssm.edu
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across the country and world, set out to establish the
molecular foundations of psychiatry. This molecular
approach to psychiatry depended on the tremendous
advances in biological psychiatry and neuropharmacology
that had taken place the previous several decades. These
advances included the development of animal models of
particular mental disorders as well as an increasingly
sophisticated understanding of the brain’s neurotransmit-
ter systems and their regulation by all major classes of
psychotropic drugs. The goals of Molecular Psychiatry, as
we first formulated them, are several fold. First, the field
aims to identify abnormalities in particular neuronal cell
types which account for the behavioral pathology seen in
the animal models of psychiatric disorders A second goal
is to understand, at the molecular and cellular levels, how
psychotropic drugs produce their clinically relevant
actions and reverse the behavioral pathology in the animal
models. A third goal is to understand how the genetic
underpinnings of an individual animal combine with a
host of environmental factors to determine the individual’s
inherent vulnerability for developing that behavioral
pathology. The fourth and ultimate goal is to translate this
information to clinical populations: to identify the genetic
variants that help determine individual risk for mental
illness, to study the molecular pathophysiology of mental
disorders in humans, and to use the increasing knowledge
of this pathophysiology to develop improved treatments,
even preventive measures, for these conditions.
Although first greeted with disbelief and even some
snickers, we achieved several milestones in those early
years that helped establish Molecular Psychiatry as a bona
fide field. Duman and I organized several symposia for the
American College of Neuropsychopharmacology and the
American Psychiatric Association in the early 1990’s. In
1993, I published a book, The Molecular Foundations of
Psychiatry, with Steve Hyman, then at Harvard and one of
our fellow pioneering molecular psychiatrists. Hyman and
I also organized a lead symposium at the Society for
Neuroscience meeting in 1995 on Molecular Psychiatry
which was widely attended. Duman, Hyman, and I, alone
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1990’s that defined this burgeoning new field and laid out
its promise for the future. By the late 1990’s the field had
matured to a point where a new journal, Molecular
Psychiatry, was formed by the Nature publishing group.
Molecular Psychiatry made it!
Further considering the field since writing the above,
despite early promise for the field, the past two decades
have been very frustrating. We have learned a great deal
about the molecular actions of psychotropic drugs and
stress in animal models, but we have not yet been able to
use this information to develop new diagnostic tests
(biomarkers) or improved treatments for mental illness.
Furthermore, only in the past 2–3 years have we begun to
identify bona fide genetic variations that confer risk for
psychiatric disease in people, and currently we have
discovered well less than 10% of the genetic causes of
these complex syndromes. Nevertheless, we remain opti-
mistic that molecular approaches will lead to revolution-
ary advances in psychiatry—the brain and its disorders are
simply far more complicated than we ever imagined. An
impressive array of new and extremely powerful experi-
mental approaches, in genetics, epigenetics, optogenetics,
multi-unit recording from awake, behaving animals, and
brain imaging, among others, should set the pace for
accelerating advances over the next decade. We hope and
expect that we will at long last witness the molecular
revolution fully transforming the field of psychiatry into a
modern medical subspecialty.
In this context, I greatly welcome the foundation of the
Journal of Molecular Psychiatry (JMP), because its modern
open-access format will further disseminate and strengthen
of the idea of molecular psychiatry.
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